Safety and tolerability of olanzapine versus risperidone: A one-year randomized study in outpatients with schizophrenia with prominent negative symptoms

Actas Espanolas de Psiquiatria

Volumn 35, Issue 2, 2007, Pages 105-114

  Ciudad, A ^a   Alvarez E ^b   Bousono M ^c   Olivares, J M ^d   Gomez J C ^a  

^a ELI LILLY AND COMPANY   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c UNIVERSIDAD DE OVIEDO   (Spain)

^d HOSPITAL XERAL CÍES   (Spain)

Author keywords

Olanzapine; Risperidone; Safety; Schizophrenia; Tolerabitity

Indexed keywords

BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ADULT; AFFECT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TOLERANCE; DRUG TOXICITY; FEMALE; HUMAN; MALE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA;

ADULT; AFFECT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DRUG TOLERANCE; DRUG TOXICITY; FEMALE; HUMANS; MALE; RISPERIDONE; SCHIZOPHRENIA;

EID: 34248142127     PISSN: 11399287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Kane JM. Schizophrenia. N Eng J Med 1996;334:34-41.
2. Kane JM. Clinical efficacy of clozapine in treatment-refractory schizophrenia: an overview. Br J Psychiatry 1992;160(Suppl. 17): 41-5.
3. Lieberman JA. Prediction of outcome in first-episode schizophrenia. J Clin Psychiatry 1993;54:13-7.
4. Corrigan PW, Liberman RP, Engel JD. From non-compliance to collaboration in the treatment of schizophrenia. Hosp Community Psychiatry 1990;41:1203-11.
5. Meltzer HY. The mechanism of action of novel antipsychotic drugs. Schizophr Bull 1991;17:263-87.
6. Kinon BJ, Lieberman JA. Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology 1996;124:2-34.
7. Tandon R, Jibson MD. Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology 2003;28(Suppl. 1):9-26.
8. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychpharmacol 1993:13:25-40.
9. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-35.
10. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br J Psychiatry 1995;166:712-726
11. Beasley CM Jr, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996:14:111-23.
12. Beasley CM Jr, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology 1996;124:159-67.
13. Tollefson GD, Beasley CM Jr, Tran PV, Street JS, Krueger JA, Tamura RN, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997:154:457-65.
14. Tollefson GD, Sanger TM. Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine Am J Psychiatry 1997;154:466-74.
15. Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C Jr, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407-18.
16. Ho BC, Miller D, Nopoulos P, Andreasen NC. A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia. J Clin Psychiatry 1999;60:658-63.
17. Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 2001;158:765-74.
18. Gureje O, Miles W, Keks N, Grainger D, Lambert T, McGrath J, et al. Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand. Schizophr Res 2003;61:303-14.
19. Gomez JC, Sacristán JA, Hernández J, Breier A, Ruiz Carrasco P, Antón Saiz C, et al for the EFESO Study Group. The safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO Study). J Clin Psychiatry 2000;61:335-43.
20. Alvarez E, Bobes J, Gómez JC, Sacristán JA, Cañas F, Carrasco JL, et al. for the EUROPA Study Group. Safety of olanzapine versus conventional antipsychotics in the treatment of patients with acute schizophrenia. A naturalistic study. Eur Neuropsychopharmacol 2003;13:39-48.
21. Andreasen NC. The scale for the assessment of negative symptom (SANS): conceptual and theoretical foundations. Br J Psychiatry 1989;155:S49-52.
22. Andreasen NC. Methods for assessing positive and negative symptoms. Mod Probl Pharmacopsychiatry 1990;24:73-88.
23. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised Version. Bethesda: US Department of Health, Education and Welfare, 1976;217-22.
24. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987;334:1-100.
25. Montejo AL, Garcia M, Espada M, Rico-Villademoros F, Llorca G, Izquierdo JA. Psychometric characteristics of the psychotropic-related sexual dysfunction questionnaire. Spanish work group for the study of psychotropic-related sexual dysfunctions. Actas Esp Psiquiatr 2000;28:141-50.
26. Fuller MA, Shermock KM, Secic M, Grogg AL. Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine Pharmacotherapy 2003;23:1037-43.
27. Koller EA, Cross JT, Doraiswamy PM, Schneider BS. Risperidone-associated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy 2003;23:735-44.
28. Bailer J, Braüer W, Rey ER. Premorbid adjustment as predictor of outcome in schizophrenia: results of a prospective study. Acta Psyciatric Scandinavica 1996;93:368-77.
29. Jackson HJ, Minas IH, Burgess PM, Joshua SD, Charisiou J, Campbell IM. Negative symptoms and social skills performance in schizophrenia. Schizophr Res 1989;2:457-63.
30. Tollefson GD, Birkett MA, Kiesler GM, Wood AJ, Lilly Resistant Schizophrenia Study Group. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol Psychiatry 2001;49: 52-63.